Why Waterford Matters to Global Pharma

Ireland's pharmaceutical reputation is well established. What is less often explored is the role that individual locations play in sustaining that success — and why County Waterford has become an increasingly important part of the country's life sciences story.

Waterford is not simply home to a collection of pharmaceutical companies. Over decades, the city and wider South-East region have built a concentration of pharmaceutical expertise, technical capability and industry knowledge that creates a strong foundation for global manufacturing and development.

A Deepening Pharmaceutical Cluster

Waterford's pharmaceutical ecosystem brings together global manufacturers, specialist suppliers, technology companies and growing CDMO capabilities. Companies including Teva, Sanofi, Eirgen Pharma and others have established operations in the region, creating an environment where pharmaceutical expertise is embedded across the local economy.

IDA Ireland has described Waterford as an important cluster for pharmaceutical manufacturing, with established companies continuing to invest in research, manufacturing and innovation.

That concentration matters. It means pharmaceutical capability is not built in isolation.

Experience, technical knowledge and specialist skills accumulate over time, creating a workforce and supply chain that understand the demands of highly regulated pharmaceutical manufacturing.

Talent That Builds On Experience

One of Waterford's most important assets is its talent base. South Eastern Technological University (SETU) offers dedicated programmes in pharmaceutical science, molecular biology and biopharmaceutical science, while also supporting research in areas including drug delivery, biotechnology and pharmaceutical analysis. SETU also delivers specialist training in Good Manufacturing Practice for people already working in the pharmaceutical industry.

This creates a valuable connection between education, industry and professional development. For companies such as Eirgen, it provides access not only to emerging scientific talent, but to an established pool of people who can continue to develop specialist expertise throughout their careers.

The ecosystem is continuing to evolve. SETU's planned Pharmacy and One Health facilities at its new Glassworks campus are intended to bring academic and enterprise activity together, further strengthening the region's capacity for collaboration, research and innovation.

An Ecosystem Built For Collaboration

The value of Waterford is therefore greater than any individual facility. It is the combination of people, infrastructure, education, industry experience and connectivity that makes the location strategically valuable.

For a global pharmaceutical company, that ecosystem can translate into something tangible: access to specialist expertise, an established manufacturing culture and a network of organisations capable of supporting increasingly complex pharmaceutical programmes.

That is particularly relevant as pharmaceutical companies seek manufacturing partners that can combine technical expertise with flexibility, scalability and speed. The question is no longer simply where a product can be manufactured. It is where the capabilities required to develop, scale and supply that product can be brought together most effectively.

Waterford's Next Chapter

Waterford's pharmaceutical story is also still being written.

The region has an established manufacturing heritage, but it is continuing to develop alongside the needs of a changing global industry. New investment, new capabilities and closer links between industry and education are expanding what the region can offer.

Eirgen Pharma is part of that evolution.

Founded in Waterford in 2005, Eirgen has grown from its early focus on high-potency pharmaceutical ingredients into a research-driven CDMO supporting the development, manufacture and supply of oral solid dose medicines for global markets.

Its continued investment demonstrates how Waterford's pharmaceutical ecosystem can support the growth of specialist manufacturing capability. Eirgen's new state-of-the-art facility increases its capacity to more than 500 million oral solid dose units annually, supporting both high-potency and non-potent products from development through to commercial supply.

The significance of that investment extends beyond additional manufacturing capacity. It demonstrates that Waterford is not simply a legacy pharmaceutical location. It is a place where new technologies, specialist skills and significant manufacturing capability continue to be developed for global markets.

For Eirgen, Waterford is more than a headquarters or manufacturing location. It is part of the company's capability — providing access to an established pharmaceutical ecosystem, a skilled talent base and a deep pool of industry knowledge.

And for global pharma, that is ultimately what makes Waterford matter: a location where experience and innovation come together to support the next generation of pharmaceutical development and manufacturing.

Eirgen Pharma's advanced manufacturing facility in Waterford

---

Ireland's pharmaceutical success story is far from complete. As global demand for complex medicines grows, and innovation accelerates, companies like Eirgen Pharma will continue to play a central role in ensuring Ireland remains at the forefront of global life sciences.